Iambic and Takeda Partner on AI-Driven Small Molecule Drug Discovery
Iambic Therapeutics has entered a multi-year collaboration with Takeda to use its AI-driven platform for small molecule drug design in oncology and gastrointestinal research, with potential payments exceeding $1.7 billion.